Find BDTX-189 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Bdtx-189, 2414572-47-5, Bdtx189, Tuxobertinib [inn], 6ce2107j4t, N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide
Molecular Formula
C29H29ClN6O4
Molecular Weight
561.0  g/mol
InChI Key
HIBPKFXWOPYJPZ-UHFFFAOYSA-N
FDA UNII
6CE2107J4T

BDTX-189
Tuxobertinib is an orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. Upon oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. EGFR and HER2, ErbB receptor tyrosine kinases mutated or overexpressed in many tumor cell types, play a key role in tumor cell proliferation and tumor vascularization.
1 2D Structure

BDTX-189

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide
2.1.2 InChI
InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)
2.1.3 InChI Key
HIBPKFXWOPYJPZ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)OCCN5CCOCC5
2.2 Other Identifiers
2.2.1 UNII
6CE2107J4T
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Bdtx-189

2. 2414572-47-5

3. Bdtx189

4. Tuxobertinib [inn]

5. 6ce2107j4t

6. N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide

7. Tuxobertinib [usan]

8. Unii-6ce2107j4t

9. Bdtx-189 [who-dd]

10. Chembl4650279

11. Schembl23450829

12. Gtpl11676

13. Ex-a4379

14. Example 8 [us11034672b1]

15. Nsc828939

16. S9786

17. Who 11817

18. Nsc-828939

19. Ac-36700

20. Hy-136789

21. Cs-0133688

22. E80424

23. N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-(2-morpholinoethoxy)quinazolin-6-yl)acrylamide

2.4 Create Date
2020-12-01
3 Chemical and Physical Properties
Molecular Weight 561.0 g/mol
Molecular Formula C29H29ClN6O4
XLogP33.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count11
Exact Mass560.1938811 g/mol
Monoisotopic Mass560.1938811 g/mol
Topological Polar Surface Area111 Ų
Heavy Atom Count40
Formal Charge0
Complexity805
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2414572-47-5 / BDTX-189 API manufacturers, exporters & distributors?

BDTX-189 manufacturers, exporters & distributors 1

92

PharmaCompass offers a list of BDTX-189 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right BDTX-189 manufacturer or BDTX-189 supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred BDTX-189 manufacturer or BDTX-189 supplier.

PharmaCompass also assists you with knowing the BDTX-189 API Price utilized in the formulation of products. BDTX-189 API Price is not always fixed or binding as the BDTX-189 Price is obtained through a variety of data sources. The BDTX-189 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

BDTX-189

Synonyms

2414572-47-5, Bdtx189, Tuxobertinib [inn], 6ce2107j4t, N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide, Tuxobertinib [usan]

Cas Number

2414572-47-5

Unique Ingredient Identifier (UNII)

6CE2107J4T

About BDTX-189

Tuxobertinib is an orally bioavailable, irreversible, selective, small-molecule inhibitor of certain oncogenic driver, allosteric mutations of the ErbB receptor tyrosine kinases epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), including extracellular domain allosteric mutations of HER2, and EGFR and HER2 exon 20 insertion mutations, with potential antineoplastic activity. Upon oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants while sparing wild-type EGFR, which may result in the selective inhibition of cellular proliferation and angiogenesis in tumor cells and tumors expressing these allosteric ErbB mutations. EGFR and HER2, ErbB receptor tyrosine kinases mutated or overexpressed in many tumor cell types, play a key role in tumor cell proliferation and tumor vascularization.

BDTX-189 Manufacturers

A BDTX-189 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BDTX-189, including repackagers and relabelers. The FDA regulates BDTX-189 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BDTX-189 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

BDTX-189 Suppliers

A BDTX-189 supplier is an individual or a company that provides BDTX-189 active pharmaceutical ingredient (API) or BDTX-189 finished formulations upon request. The BDTX-189 suppliers may include BDTX-189 API manufacturers, exporters, distributors and traders.

BDTX-189 GMP

BDTX-189 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of BDTX-189 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right BDTX-189 GMP manufacturer or BDTX-189 GMP API supplier for your needs.

BDTX-189 CoA

A BDTX-189 CoA (Certificate of Analysis) is a formal document that attests to BDTX-189's compliance with BDTX-189 specifications and serves as a tool for batch-level quality control.

BDTX-189 CoA mostly includes findings from lab analyses of a specific batch. For each BDTX-189 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

BDTX-189 may be tested according to a variety of international standards, such as European Pharmacopoeia (BDTX-189 EP), BDTX-189 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BDTX-189 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty